Poly(ADP-ribose) polymerase activation in the reperfused myocardium

Gábor Szabó, Lucas Liaudet, Siegfried Hagl, Csaba Szabo

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

The activation of poly(ADP-ribose) polymerase (PARP) is now considered a final common effector in various types of tissue injury including systemic inflammation, circulatory shock and ischemia/reperfusion. Free radical and oxidant production and related cytotoxicity during ischemia/reperfusion leads to DNA strand breakage which activates the nuclear enzyme PARP and initiates an energy-consuming, inefficient cellular metabolic cycle with transfer of the ADP-ribosyl moiety of NAD+ to protein acceptors. During the last 5 years, a growing number of experimental studies demonstrated the beneficial effects of PARP inhibition in cell cultures through rodent models and more recently in pre-clinical large animal models of regional and global ischemia/reperfusion injury. The objective of the current review is to provide an overview of the experimental evidence implicating PARP as a pathophysiological modulator of myocardial injury in vitro and in vivo.

Original languageEnglish
Pages (from-to)471-480
Number of pages10
JournalCardiovascular Research
Volume61
Issue number3
DOIs
StatePublished - Feb 15 2004
Externally publishedYes

Fingerprint

Poly(ADP-ribose) Polymerases
Myocardium
Reperfusion
Ischemia
Wounds and Injuries
Reperfusion Injury
Oxidants
NAD
Adenosine Diphosphate
Free Radicals
Rodentia
Shock
Animal Models
Cell Culture Techniques
Inflammation
DNA
Enzymes
Proteins

Keywords

  • Heart
  • Oxidative stress
  • Peroxynitrite
  • Poly(ADP-ribose) polymerase
  • Reperfusion injury

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Poly(ADP-ribose) polymerase activation in the reperfused myocardium. / Szabó, Gábor; Liaudet, Lucas; Hagl, Siegfried; Szabo, Csaba.

In: Cardiovascular Research, Vol. 61, No. 3, 15.02.2004, p. 471-480.

Research output: Contribution to journalArticle

Szabó, Gábor ; Liaudet, Lucas ; Hagl, Siegfried ; Szabo, Csaba. / Poly(ADP-ribose) polymerase activation in the reperfused myocardium. In: Cardiovascular Research. 2004 ; Vol. 61, No. 3. pp. 471-480.
@article{e93fea1d70c54344bb93dd1aa29ec40b,
title = "Poly(ADP-ribose) polymerase activation in the reperfused myocardium",
abstract = "The activation of poly(ADP-ribose) polymerase (PARP) is now considered a final common effector in various types of tissue injury including systemic inflammation, circulatory shock and ischemia/reperfusion. Free radical and oxidant production and related cytotoxicity during ischemia/reperfusion leads to DNA strand breakage which activates the nuclear enzyme PARP and initiates an energy-consuming, inefficient cellular metabolic cycle with transfer of the ADP-ribosyl moiety of NAD+ to protein acceptors. During the last 5 years, a growing number of experimental studies demonstrated the beneficial effects of PARP inhibition in cell cultures through rodent models and more recently in pre-clinical large animal models of regional and global ischemia/reperfusion injury. The objective of the current review is to provide an overview of the experimental evidence implicating PARP as a pathophysiological modulator of myocardial injury in vitro and in vivo.",
keywords = "Heart, Oxidative stress, Peroxynitrite, Poly(ADP-ribose) polymerase, Reperfusion injury",
author = "G{\'a}bor Szab{\'o} and Lucas Liaudet and Siegfried Hagl and Csaba Szabo",
year = "2004",
month = "2",
day = "15",
doi = "10.1016/j.cardiores.2003.09.029",
language = "English",
volume = "61",
pages = "471--480",
journal = "Cardiovascular Research",
issn = "0008-6363",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Poly(ADP-ribose) polymerase activation in the reperfused myocardium

AU - Szabó, Gábor

AU - Liaudet, Lucas

AU - Hagl, Siegfried

AU - Szabo, Csaba

PY - 2004/2/15

Y1 - 2004/2/15

N2 - The activation of poly(ADP-ribose) polymerase (PARP) is now considered a final common effector in various types of tissue injury including systemic inflammation, circulatory shock and ischemia/reperfusion. Free radical and oxidant production and related cytotoxicity during ischemia/reperfusion leads to DNA strand breakage which activates the nuclear enzyme PARP and initiates an energy-consuming, inefficient cellular metabolic cycle with transfer of the ADP-ribosyl moiety of NAD+ to protein acceptors. During the last 5 years, a growing number of experimental studies demonstrated the beneficial effects of PARP inhibition in cell cultures through rodent models and more recently in pre-clinical large animal models of regional and global ischemia/reperfusion injury. The objective of the current review is to provide an overview of the experimental evidence implicating PARP as a pathophysiological modulator of myocardial injury in vitro and in vivo.

AB - The activation of poly(ADP-ribose) polymerase (PARP) is now considered a final common effector in various types of tissue injury including systemic inflammation, circulatory shock and ischemia/reperfusion. Free radical and oxidant production and related cytotoxicity during ischemia/reperfusion leads to DNA strand breakage which activates the nuclear enzyme PARP and initiates an energy-consuming, inefficient cellular metabolic cycle with transfer of the ADP-ribosyl moiety of NAD+ to protein acceptors. During the last 5 years, a growing number of experimental studies demonstrated the beneficial effects of PARP inhibition in cell cultures through rodent models and more recently in pre-clinical large animal models of regional and global ischemia/reperfusion injury. The objective of the current review is to provide an overview of the experimental evidence implicating PARP as a pathophysiological modulator of myocardial injury in vitro and in vivo.

KW - Heart

KW - Oxidative stress

KW - Peroxynitrite

KW - Poly(ADP-ribose) polymerase

KW - Reperfusion injury

UR - http://www.scopus.com/inward/record.url?scp=1142285446&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1142285446&partnerID=8YFLogxK

U2 - 10.1016/j.cardiores.2003.09.029

DO - 10.1016/j.cardiores.2003.09.029

M3 - Article

C2 - 14962478

AN - SCOPUS:1142285446

VL - 61

SP - 471

EP - 480

JO - Cardiovascular Research

JF - Cardiovascular Research

SN - 0008-6363

IS - 3

ER -